"You'd have to have your head in the sand if you didn't at least assume that every professional sport might have some sort of performing-enhancing drugs being used," Evert told a conference call from Indian Wells, where she will do TV commentary for ESPN at the BNP Paribas Open.
"Honestly, in every professional sport I think this goes on to a certain extent. In tennis it doesn't worry me as much. This went on when I was playing."
"I know players on the women's tour who were using -- who were using performance‑enhancing drugs and we didn't even have drug testing."
News that makes sense
Your trusted source for staying up-to-date with the world around you. Get free daily news updates and analysis, straight to your inbox.
Sharapova faces up to a four-year ban by the International Tennis Federation for testing positive for meldonium in January, a drug she had taken for 10 years due to health problems and which was banned on Jan. 1.
Evert feels the length of Sharapova's ban will hinge on her medical records and that the former Russian world number one may only deserve to be barred for the rest of the year.
"It all comes down to viewing the medical records from the doctors that took care of her 10 years ago and examining exactly what her case is," said Evert.
"This drug is used for angina and severe heart issues. There's always suspicion when you hear what the drug is used for. That's why her defence needs to show medical records, and (her) dosage.
"If it does come out cleanly, I would say banning her for the rest of year would be enough."
Evert's ESPN colleague Patrick McEnroe said players always look for an advantage.
"Players of course are going to look to get an edge, whether in how they train, or in how they eat and how they recover," the former U.S. David Cup captain said.
"Do I think it’s a major problem in tennis? No, I don't. I think the testing is very tough in tennis."
(Reporting by Larry Fine in New York; Editing by Frank Pingue)
